The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs.

Abstract

It is unknown to what extent rising drug costs are due to inflation in the prices of existing drugs versus the entry of new products. We used pricing data from First Databank and pharmacy claims from UPMC Health Plan to quantify the contribution of new versus existing drugs to the changes in costs of oral and injectable drugs used in the outpatient setting in 2008-16. The costs of oral and injectable brand-name drugs increased annually by 9.2\xa0percent and 15.1\xa0percent, respectively, largely driven by existing drugs. For oral and injectable specialty drugs, costs increased 20.6\xa0percent and 12.5\xa0percent, respectively, with 71.1\xa0percent and 52.4\xa0percent of these increases attributable to new drugs. Costs of oral and injectable generics increased by 4.4\xa0percent and 7.3\xa0percent, respectively, driven by new drug entry. The rising costs of generic and specialty drugs were mostly driven by new product entry, whereas the rising costs of brand-name drugs were due to existing drug price inflation.